Business Wire
02 Nov 2026, 11:42 UTC · 22h ago
Impact · against what's priced in
The publication of UNICORN Phase 2 results in Nature Medicine provides external validation for Agenus's neoadjuvant colon cancer approach. This reduces clinical risk and clarifies the path toward Phase 3 trial design.
No priced-in read yet
What the story claims
1 claim · scored −1 bearish … +1 bullish · 1 new · 0 priced in
Agenus announced the peer-reviewed publication of results from the Phase 2 UNICORN trial for neoadjuvant botensilimab and balstilimab in resectable colon cancer.
Newannouncement dated 2026-11-02
So whatPeer-reviewed validation in Nature Medicine typically accelerates the path toward Phase 3 trial design and potential regulatory fast-track designations.
More positive than 92% of claims this week
Which stocks this story touches
Continue reading
5 related stories
The peer-reviewed publication of deep responses in resectable colon cancer validates the efficacy of the BOT+BAL combination, potentially accelerating regulatory timelines.
Read from the article alone
Scored by the NIS engine · methodology.
More positive than 73% of ticker scores this week
The company announced the peer-reviewed publication of Phase 2 trial results for its cancer treatments.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
GlobeNewsWire
1d ago
−4.5%
Price is moving against the score
$6.53 vs $6.84 close before publication (Oct 30) · not market-adjusted
AGEN chart →
